Our top pick for
Building a portfolio
Amyris, Inc is a specialty chemicals business based in the US. Amyris shares (AMRS) are listed on the NASDAQ and all prices are listed in US Dollars. Amyris employs 595 staff and has a trailing 12-month revenue of around USD$173.1 million.
|52-week range||USD$1.88 - USD$23.42|
|50-day moving average||USD$18.1529|
|200-day moving average||USD$8.583|
|Wall St. target price||USD$26.6|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.388|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$173.1 million|
|Gross profit TTM||USD$14.8 million|
|Return on assets TTM||-40.2%|
|Return on equity TTM||0%|
|Market capitalisation||USD$4.5 billion|
TTM: trailing 12 months
There are currently 21.7 million Amyris shares held short by investors – that's known as Amyris's "short interest". This figure is 7.9% up from 20.2 million last month.
There are a few different ways that this level of interest in shorting Amyris shares can be evaluated.
Amyris's "short interest ratio" (SIR) is the quantity of Amyris shares currently shorted divided by the average quantity of Amyris shares traded daily (recently around 5.6 million). Amyris's SIR currently stands at 3.86. In other words for every 100,000 Amyris shares traded daily on the market, roughly 3860 shares are currently held short.
However Amyris's short interest can also be evaluated against the total number of Amyris shares, or, against the total number of tradable Amyris shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Amyris's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 Amyris shares in existence, roughly 80 shares are currently held short) or 0.1377% of the tradable shares (for every 100,000 tradable Amyris shares, roughly 138 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Amyris.
Find out more about how you can short Amyris stock.
We're not expecting Amyris to pay a dividend over the next 12 months.
Amyris's shares were split on a 1:15 basis on 5 June 2017. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Amyris shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Amyris shares which in turn could have impacted Amyris's share price.
Over the last 12 months, Amyris's shares have ranged in value from as little as $1.88 up to $23.42. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amyris's is 1.235. This would suggest that Amyris's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty markets through its consumer brands and as a supplier of sustainable and natural ingredients in Europe, the United States, Asia, Brazil, and internationally. It manufactures and sells products for the health and wellness, clean beauty, and flavor and fragrance markets. The company operates under the Amyris, Biofene, Biossance, Pipette, Purecane, and No Compromise trademarks. Amyris, Inc. has a collaboration agreement with the Infectious Disease Research Institute to advance a novel ribonucleic acid vaccine platform, including accelerating the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.
Steps to owning and managing PNRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing PINC, with 24-hour and historical pricing before you buy.
Steps to owning and managing POAI, with 24-hour and historical pricing before you buy.
Steps to owning and managing PBTS, with 24-hour and historical pricing before you buy.
Steps to owning and managing PTMN, with 24-hour and historical pricing before you buy.
Steps to owning and managing BPOP, with 24-hour and historical pricing before you buy.
Steps to owning and managing PLYA, with 24-hour and historical pricing before you buy.
Steps to owning and managing PAGP, with 24-hour and historical pricing before you buy.
Steps to owning and managing PAA, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.